PulseSight has completed follow-up on all six patients in its first-in-human PST-611 study for geographic atrophy secondary to dry AMD and will present the Phase I readout at ARVO 2026. The single-center dose-escalation trial evaluated two dose levels to assess safety and tolerability of a non-viral, plasmid-based gene therapy delivered to the ciliary muscle via electro-transfection, with the aim of achieving sustained intraocular expression of transferrin.
The immediate news is a formal transition from enrollment and follow-up to public disclosure. The company has locked the data set from its two-cohort Phase I and secured an oral slot at ARVO. Details remain under wraps ahead of the meeting, but the program’s core thesis is clear: modulating retinal iron homeostasis to counter oxidative stress and ferroptosis, rather than targeting complement components, and doing so through a minimally invasive, device-enabled gene therapy intended to deliver broad retinal distribution without viral vectors or subretinal surgery.
Strategically, this is an orthogonal bet in a GA market that has coalesced around complement inhibition with acknowledged trade-offs in administration burden and inflammation risk. By pairing a non-viral plasmid with ciliary muscle transfection, PulseSight is positioning for re-dosing flexibility and potentially lower immunogenicity versus AAV approaches, while avoiding the surgical complexity of subretinal delivery. If the trans-scleral diffusion from the ciliary muscle reliably achieves therapeutic retinal levels, the platform could support durable protein expression with lower operational friction than chronic intravitreal injections or surgical gene therapy. The countervailing risk is execution at the interface of drug and device: consistency of transfection, procedure standardization across sites, and a regulatory path that may straddle gene therapy and combination-product oversight.
For sites, the operational footprint differs from both injection clinics and vitreoretinal OR settings. Adopting an electro-transfection system introduces device training, procedure-specific SOPs, and equipment maintenance, but could remain office-based if the procedure proves predictable and well tolerated. CROs and imaging vendors should expect a Phase IIa design to lean heavily on multimodal imaging—particularly fundus autofluorescence to track GA lesion area—alongside functional measures, with centralized reading to manage variability. Regulators will focus on ocular safety signals typical of gene and device-mediated delivery, including intraocular inflammation, IOP excursions, choroidal or ciliary body effects, and any impact on conversion to neovascular AMD. Manufacturing and CMC workstreams will center on GMP plasmid production and device reliability, both of which carry scale-up implications distinct from biologics or AAV.
The near-term question is whether ARVO will provide more than first-pass safety. Early feasibility markers to watch include procedure success rates, adjudicated ocular AEs, durability of expression proxies if sampled in aqueous humor, and any directional signals on lesion growth or visual function despite the small n and Phase I scope. The company’s outline for Phase IIa will be equally informative: randomization and sham control, dose selection, re-dosing intervals, geographic footprint across EU and US, and powering assumptions for lesion growth reduction over 12 months. Clarity on long-term follow-up requirements, device regulatory classification, and plans for independent procedure training will indicate how quickly PulseSight can scale beyond two French centers.
If the safety profile is clean and feasibility holds, PulseSight could broaden the debate in GA beyond complement biology and toward sustained, office-based protein expression. The burden of proof will be quantitative: reproducible delivery, measurable pharmacodynamic activity, and credible anatomic efficacy within a controlled study. Absent that, the platform risks being categorized as an elegant procedure in search of a clinical signal. Executives should watch for the rigor of Phase IIa protocol design, the choice of endpoints, and whether the company aligns early with FDA and EMA on gene therapy and combination-device expectations.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
